Product Description
Mechanisms of Action: PAC1 Agonist
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Universitaire Ziekenhuizen KU Leuven
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CCP14-3301-PAC1 | P1 |
Completed |
Healthy Volunteers |
2015-04-01 |